 |
|
 |
|
|
|
 What is RSS?
Novartis files COX-II contender amid class safety concerns
Novartis has submitted its COX-II inhibitor Prexige to US and European regulators with data from 13,000 clinical trial patients to prove its safety and efficacy profile...(more)
NHS pay rise linked to reform
Workers throughout the NHS are to receive substantial pay rises in return for undergoing radical ob evaluationreviews over the next three years...(more)
Increase marketing RoI or cut back, analysts warn
Pharmaceutical companies must make their sales and marketing more cost-effective or cut back, according to a new report...(more)
Supplementary prescribing gets go ahead
Thousands of trained pharmacists and nurses will be able to prescribe drugs for chronic diseases by late 2004, the Government has announced...(more)
OGS extends Actelion relationship as Zavesca approved
Oxford GlycoSciences has announced the EU approval of its first product, Zavesca, and an extension to its co-marketing agreement with Actelion...(more)
BMS schizophrenia drug wins US approval
New atypical antipsychotic Abilify has gained FDA approval for the treatment of schizophrenia and is tipped to eventually become a blockbuster for manufacturers Bristol-Myers Squibb...(more)
Garnier to concede on pay demands
GlaxoSmithKline's Chief Executive Jean-Pierre Garnier is to back down on demands for a hugely increased pay package after fierce criticism from shareholders...(more)
National service framework leaders appointed
Key appointments for the Children National Service Framework and the Long-term Conditions National Service Framework have been announced...(more)
Red tape could suffocate European clinical trials
New measures intended to improve the competitiveness of clinical trials in Europe could have the opposite effect, a leading research head has warned...(more)
New Bextra warnings add to COX-II doubts
New warnings on the label of second-generation COX-II inhibitor Bextra have added to doubts about the safety of the drug class...(more)
Pharma companies offer NHS 'cash-back' on smoking cessation products
Leading pharmaceutical companies in the smoking cessation market have struck a groundbreaking deal with the Government to offer ash-backto the NHS to encourage uptake of the products...(more)
Government presses on with MCA merger
The UK Government is to press ahead with the merger of the Medicines Control Agency and its medical devices counterpart despite uncertainty surrounding the future of drug regulation in Europe...(more)
Bayer parallel import case reopened
A landmark legal battle over parallel trade of Bayer blood pressure treatment Adalat has been re-commenced in the European Court of Justice...(more)
Best time ever to be biotech, says Evans
There has never been a better time to be a biotech company, despite the financial gloom in the sector, according to entrepreneur Sir Christopher Evans...(more)
Record $20m stem cell research investment
US-based Juvenile Diabetes Research Foundation is to invest at least $20 million into stem cell research at sites in Britain, Sweden, Australia and Singapore...(more)
Antisoma hails 'ground-breaking' Roche cancer deal
Roche has bought the exclusive world-wide rights to Antisoma oncology pipeline in a deal the biotech company chief executive has called round-breaking...(more)
New FDA head promises improvements for workforce
The new FDA Commissioner, Dr Mark McClellan, has pledged that improvements in the working lives of staff will be a top priority...(more)
Pharmacia man tipped to head Celltech
Pharmacia Head of Research and Development, Goran Ando, is tipped to become Celltech new Chief Executive when its current incumbent steps down...(more)
Local people to control foundation hospitals
Local people are to play a major role in deciding how the new, more autonomous foundation hospitals are to be run...(more)
WTO close to agreeing medicines supply deal
World Trade Organisation ministers say they are close to striking a deal aimed at improving the provision of medicines to developing nations...(more)
'Smart' cancer drugs share top honours in drug innovation prize
The innovative science behind two breakthrough cancer drugs, Novartisleukaemia treatment Glivec and Roche breast cancer drug Herceptin, has been recognised in the prestigious UK Prix Galien awards...(more)
Kogan steps down from troubled Schering
Richard Jay Kogan has stepped down as Chairman of Schering-Plough and will relinquish his post as Chief Executive and President in time for the company AGM next April...(more)
Novartis questions AstraZeneca cancer data
Novartis has questioned the evidence behind a UK licence extension to AstraZeneca breast cancer drug Arimidex...(more)
NHS palliative care gets £10m boost
An extra £10 million for specialist palliative care services will be available for local cancer services around the country...(more)
Cozaar gains renal protection licence
Merck Sharpe & Dohme Cozaar has gained a new UK licence for renal protection in patients with type II diabetes and nephropathy...(more)
Lilly to launch three products in 2003
Eli Lilly is to embark on an ambitious product launch schedule over the next two years to overcome the patent loss of its biggest earning product, Prozac, in 2001...(more)
Bayer open to takeover bids
The Chief Executive of Bayer has conceded the company cannot continue alone, and has now declared the company open to takeover offers from pharmaceutical rivals...(more)
Flu vaccines lead PowderJect growth
UK vaccines manufacturer PowderJect has seen its profits rise on the back of strong sales of its flu vaccine Fluvirin...(more)
Alzheimer drugs rationing continues despite NICE guidelines
Alzheimer patients in a quarter of all health authorities are still not receiving the latest medicines despite NICE guidance being in place for nearly two years...(more)
British Biotech to pursue merger
The Chairman of British Biotech has reiterated the company aim to pursue an acquisition or merger following the departure of Chief Executive Dr Elliot Goldstein...(more)
GSK doubles In2Focus NiQuitin team
GlaxoSmithKline Consumer Healthcare is to expand its use of In2Focus sales representatives to promote its smoking cessation product NiQuitin CQ in the UK...(more)
Doctors reject Milburn latest contract idea
Doctors' leaders have rejected Heath Secretary Alan Milburn latest idea to break the deadlock over the new consultant contract...(more)
Europe to mimic US research 'clusters'
New networks of excellence in pharmaceutical research must be established if Europe is to catch up with world leading US R&D communities, according to the European Commission...(more)
Crestor approval lifts AstraZeneca
AstraZeneca has been boosted by the first regulatory approval in the Netherlands of Crestor, its uperstatincholesterol treatment...(more)
OTC advertising regulations to be relaxed
A ban on advertising some OTC medicines could be lifted as part of the Government drive to create a patient-centred NHS...(more)
Superstatins could face NICE review
The next generation of statins such as AstraZeneca Crestor could face a NICE review because of cost concerns, the Government Heart Czar Dr Roger Boyle has revealed...(more)
Patients to report drug side-effects to NHS
Patients will be able to report adverse reactions to medicines direct to the NHS from next year, the Government has revealed...(more)
AZ launches Zomig nasal spray
AstraZeneca has launched a new fast acting nasal spray version of its migraine treatment Zomig...(more)
Key products drive Aventis in Q3
Aventis is on track to hit its full-year targets following strong third-quarter performance of key products...(more)
Prilosec OTC launch delayed
Procter & Gamble's proposed launch of an over-the-counter version of AstraZeneca¿s blockbuster Prilosec will be delayed after the FDA requested changes to its label design...(more)
New ABPI campaign promotes industry reputation
The ABPI has launched an advertising campaign aimed at promoting the benefits the pharmaceutical industry brings to the UK. ..(more)
BMS to restate $2bn earnings
Bristol-Myers Squibb has been forced to restate more than $2 billion of earnings as a result of what it terms a ..(more)
Cancer research map unveiled
The UK's biggest cancer killer is the one of the most under-funded, according to a new map of cancer research...(more)
Amersham on track for full year targets
Amersham will fulfil its full year forecasts, despite a slower than expected third quarter the medical diagnostics and life sciences company said...(more)
Pfizer sues struggling GSK over Viagra patent
Pfizer has filed a patent infringement suit against two new products from GlaxoSmithKline, Bayer and Eli Lilly to protect the market dominance of impotence treatment Viagra...(more)
Pharma websites not defending company reputation
Few companies within the UK sector communicate properly via the Internet, according to a new report that found key messages on essential issues missing in many cases...(more)
Ashfield buys rival field force provider for £4.8m
Contract sales organisation Ashfield Healthcare has increased its share of the UK market to around 40% with the acquisition of rival Ventiv UK...(more)
Bayer healthcare chief quits
The head of Bayer healthcare unit, Frank Morich, has resigned as troubles at the German company continue...(more)
Shire's chief steps down
Shire's chief executive Rolf Stahel is to stand down after reports of a widening rift with US non-executive directors and shareholders...(more)
Elan running $1bn loss
Elan reported a net loss of $1 billion for the third quarter, following charges of $943 million...(more)
Medicines Partnership would involve industry
The Medicines Partnership, a Department of Health scheme that promotes patient compliance, would lend its support to pharmaceutical industry projects...(more)
Pharma faces outcome of EU balancing act
Negotiations on the future of the European pharmaceutical industry have stepped up a gear after a crucial vote in the European Parliament in Strasbourg...(more)
Claritin sales slump ahead of OTC switch
Profits at Schering-Plough have been hit by the company search for a follow-up to its blockbuster allergy drug Claritin...(more)
Health authorities blocking change, say PCTs
Strategic health authorities are too far removed from PCTs to help them innovate as they work on their plans for the future, according to the NHS Alliance...(more)
DoH admits hospital star error
The Department of Health has admitted a statistical error meant a hospital was wrongly graded as two-star...(more)
Network to encourage
The NHS is to be given more support to work in partnership with local authorities with the establishment of the Integrated Care Network...(more)
Pharma satirist nearly unmasked
The anonymous prankster behind the pharma industry satire www.selldrugs.net has broken his silence in an exclusive interview with Pharmafocus...(more)
|
|
|
|
|
|
|
|
|
|
|
